Solitary beta-blocker therapy for idiopathic life-threatening ventricular tachyarrhythmias.
To determine the clinical characteristics of patients with life-threatening ventricular tachyarrhythmias with no identifiable heart disease, we analyzed six patients who presented with either cardiac arrest or syncope associated with documented ventricular tachycardia or fibrillation. Electrocardiographic and echocardiographic examination and cardiac catheterization results were normal in all patients. Electrocardiographic monitoring revealed ventricular tachycardia in all patients. Exercise testing did not provoke sustained ventricular tachycardia in any patient. Programmed extrastimulation did not induce ventricular tachycardia in any patient. Isoproterenol infusion facilitated provocation of sustained ventricular tachycardia in only one patient. All six patients were treated with solitary beta-blocker therapy. Following treatment, there was a significant reduction in the incidence of ventricular tachycardia, couplets and total ventricular ectopic beats. During a follow-up period ranging from 16 to 36 (mean 22) months, all patients remain alive without clinically significant recurrence. Therefore, patients with life-threatening ventricular tachyarrhythmias without identifiable heart disease may respond to solitary beta-blocker therapy.
Brodsky
M A
MA
Sato
D A
DA
Allen
B J
BJ
Chesnie
B M
BM
Henry
W L
WL
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D002319:Cardiovascular System / Q000503:physiopathology; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D005500:Follow-Up Studies; D006334:Heart Function Tests; D006352:Heart Ventricles; D006801:Humans; D008875:Middle Aged; D013610:Tachycardia / Q000188:drug therapy*; D014693:Ventricular Fibrillation / Q000188:drug therapy*
D000319:Adrenergic beta-Antagonists